Skip to main content
main-content
Top

05-16-2022 | Tirzepatide | News

approvalsWatch

Tirzepatide gets nod from US FDA

Author: Eleanor McDermid

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: The FDA has approved the first-in-class, dual-action medication tirzepatide for glucose lowering in people with type 2 diabetes.

The decision is based on findings from the five clinical trials so far published from the SURPASS series. These showed significantly greater glucose reductions with tirzepatide compared with placebo, semaglutide, and insulin degludec and glargine in various study populations, as well as substantial reductions in bodyweight.

The cardiovascular outcomes trial – SURPASS-CVOT – is ongoing.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

ADA 2022 coverage

Access the latest news and expert insight from the ADA 82nd Scientific Sessions

Related content

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials

Phase 3 trials of tirzepatide in type 2 diabetes and obesity